U.S. Markets closed

Better Plant Sciences Inc. (BOSQF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0712-0.0010 (-1.39%)
At close: 3:46PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0722
Open0.0766
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0670 - 0.0766
52 Week Range0.0435 - 0.2370
Volume316,416
Avg. Volume301,384
Market Cap9.342M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Better Plant Launches Urban Juve Loyalty Program with LoyaltyLion
    Newsfile

    Better Plant Launches Urban Juve Loyalty Program with LoyaltyLion

    Vancouver, British Columbia--(Newsfile Corp. - November 24, 2020) - Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) ("Better Plant") or (the "Company") is pleased to announce the launch of a customer rewards program called "Insider Rewards" for its Urban Juve skin care line. Better Plant Launches Urban Juve Loyalty Program with LoyaltyLionTo view an enhanced version of this image, please visit:https://orders.newsfilecorp.com/files/6377/68816_d5e319fef42e2b1a_001full.jpg"Insider Rewards will give our customers the opportunity to collect points ...

  • NeonMind Commences Preclinical Trial to Examine Psilocybin for Weight Loss
    Newsfile

    NeonMind Commences Preclinical Trial to Examine Psilocybin for Weight Loss

    Vancouver, British Columbia--(Newsfile Corp. - November 19, 2020) - Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) ("Better Plant") or (the "Company") is pleased to announce that its majority owned subsidiary NeonMind Biosciences Inc. ("NeonMind") has now commenced a psilocybin preclinical trial examining psilocybin as a potential treatment to promote and cause weight loss and to reduce food cravings (the "Trial") after obtaining Health Canada approval. The Trial is being conducted by ...

  • Newsfile

    Psilocybin Could Unlock Key Mental Health Treatments for Millions of People

    Houston, Texas--(Newsfile Corp. - November 18, 2020) - Psilocybin could be the key to unlocking key treatments for mental health issues. "Existing antidepressant drugs don't work well for an estimated 30 to 50 percent of the people who try them; when they do work, the effects can take weeks to kick in. Psilocybin, a compound that can profoundly alter consciousness and perceptions of reality, might be a powerful alternative, says Roland Griffiths, a neuropsychopharmacologist ...